Amgen, Inc. acknowledged during its business review on 8 February that drug pricing and competitive pressures are growing hurdles for the biopharmaceutical industry through the end of this decade. As a result, Amgen has spent the past decade investing in a research and development platform that is designed to meet those challenges head on.
Amgen Rebuilt R&D Platform To Focus On Speed And Access
Genetics, AI And Other Tools Assembled Over Past Decade
The company explained during its recent business review how its R&D organization is pursuing the strategic objectives of improving success rates, reducing cycle times and enabling access to novel drugs.
